YOLFTbeta
Compass Pathways Plc

Compass Pathways Plc

CMPS · NASDAQ · Healthcare / Medical Care Facilities

9.01USD-0.11 (-1.21%)

Price History

Full chart

Market Stats

Previous Close9.12
Open9.01
Day Range8.53 – 9.16
52-Week Range4.88 – 15.87
Volume2.62M
Market Cap1.81B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.79
Dividend Yield0.00%
Beta2.55
50-Day Avg13.30
200-Day Avg9.75

About

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryMedical Care Facilities
  • CEOMr. Kabir Kumar Nath M.A., M.B.A.
  • Employees156
  • Headquarters33 Broadwick Street, London, United Kingdom, W1F 0DQ, USA
  • Websitehttps://compasspathways.com

Leadership

  • Mr. Kabir Kumar Nath M.A., M.B.A.CEO & Executive Director · b. 1964
  • Ms. Teri Loxam M.B.A.Chief Financial Officer · b. 1973
  • Dr. Guy GoodwinChief Medical Officer · b. 1948
  • Mr. Stephen D. SchultzSenior Vice President of Investor Relations
  • Mr. Lars Christian WildeSenior Advisor · b. 1986
  • Dr. Susan C. Stansfield Ph.D.Advisor
  • Dr. Michael Gold M.D., M.Sc.Chief Research & Development Officer · b. 1961
  • Ms. Lori Englebert M.B.A.Chief Commercial Officer · b. 1978
  • Dr. Steve Levine M.D.Chief Patient Officer
  • Mr. Benjamin HarberCompany Secretary · b. 1977

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000000
Cost of Revenue-63.00K112.87K174.98K329.80K242.94K233.10K216.50K
Gross Profit--63.00K-112.87K-174.98K-329.80K-242.94K-233.10K-216.50K
Operating Expense-21.12M51.68M83.05M110.07M136.68M177.97M178.82M
Operating Income-12.50M-21.18M-51.79M-83.22M-110.40M-136.92M-178.21M-179.04M
EBITDA-10.52M-22.26M-64.94M-71.37M-90.77M-115.24M-148.82M-285.60M
Net Income-13.22M-19.61M-60.80M-71.74M-91.50M-118.46M-155.12M-287.86M
R&D8.92M12.56M23.37M44.03M65.05M87.52M119.04M118.44M
Interest Expense01.15M24.74M4.20M6.03M2.20M4.48M4.52M

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets26.39M32.39M203.46M300.90M197.29M275.99M213.67M210.35M
Total Liabilities40.75M23.87M6.89M16.49M16.01M50.24M58.97M263.20M
Total Equity-14.37M8.52M196.56M284.41M181.28M225.74M154.69M-52.85M
Cash22.91M24.97M190.33M273.24M143.21M220.20M165.08M149.61M
Total Debt-21.09M-3.61M1.93M33.05M32.19M20.93M
Net Debt-22.91M-3.88M-190.33M-269.63M-141.28M-187.15M-132.89M-128.68M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.80M-17.81M-41.38M-67.75M-105.45M-97.38M-119.19M-157.24M
Investing Cash Flow-130.00K-165.00K-628.00K-334.00K-596.00K-64.00K--
Financing Cash Flow32.96M18.38M194.16M156.65M1.04M173.83M63.82M140.71M
Capital Expenditure130.00K165.00K131.00K334.00K596.00K66.00K00
Free Cash Flow-9.93M-17.98M-41.51M-68.08M-106.05M-97.44M-119.19M-157.24M
FCF to OCF101.33%100.93%100.32%100.49%100.57%100.07%100.00%100.00%

Earnings

Report DateSep 21, 2020Nov 12, 2020Mar 9, 2021May 13, 2021Aug 11, 2021Nov 9, 2021Feb 24, 2022May 10, 2022Aug 4, 2022Nov 3, 2022Feb 28, 2023May 11, 2023Aug 3, 2023Nov 2, 2023Feb 29, 2024May 8, 2024Aug 1, 2024Oct 31, 2024Feb 26, 2025May 8, 2025Jul 31, 2025Nov 4, 2025Feb 26, 2026May 13, 2026Aug 5, 2026Nov 3, 2026
EPS Estimate-0.35-0.68-1.39-0.47-0.37-0.47-0.50-0.67-0.60-0.64-0.59-0.65-0.70-0.42-0.34-0.49-0.55-0.59-0.63-0.49-0.37-0.40-0.40-0.31-0.46-0.42
EPS Actual-0.19-0.46-0.52-0.35-0.44-0.38-0.61-0.50-0.50-0.43-0.73-0.57-0.62-0.67-0.53-0.55-0.56-0.56-0.63-0.42-0.41-0.38-0.61-0.30-0.36-
Surprise45.71%32.35%62.59%25.53%-18.92%19.15%-22.00%25.37%16.67%32.81%-23.73%12.31%11.43%-59.52%-55.88%-12.24%-1.82%5.08%0.00%14.29%-10.81%5.00%-52.66%3.23%21.74%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.81B
Enterprise Value1.53B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book22.52
EPS-3.79
Book Value0.623
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-185.56M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-319.07%
Return on Assets-29.08%
Shares Outstanding138.48M
Shares Float106.97M
Beta2.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 23.75
  • Strong Buy
    7
  • Buy
    4

Ownership Breakdown

Institutions
68.43%
Insiders
7.62%
Retail / Other
23.95%

Top Institutional Holders

  • Deep Track Capital, LP
    12.16M8.78%
  • RTW INVESTMENTS, LLC
    10.63M7.68%
  • Two Sigma Investments LLC
    4.47M3.23%
  • Marshall Wace Asset Management Ltd
    4.04M2.92%
  • TANG CAPITAL MANAGEMENT LLC
    4.00M2.89%
  • ARK Investment Management LLC
    3.30M2.38%
  • Baker Bros Advisors LP
    2.34M1.69%
  • Logos Global Management LP
    2.25M1.62%
  • Eagle Health Investments LP
    2.06M1.49%
  • Dafna Capital Management LLC
    2.01M1.45%
  • UBS Group AG
    1.86M1.34%
  • NEXTBio Capital Management LP
    1.78M1.28%
  • Kalehua Capital Management LLC
    1.64M1.18%
  • Caption Management, LLC
    1.61M1.16%
  • Heights Capital Management Inc
    1.49M1.08%
  • Jefferies Financial Group Inc
    1.47M1.06%
  • Aisling Capital Management LP
    1.43M1.03%
  • Morgan Stanley - Brokerage Accounts
    1.21M0.87%

Top Fund Holders

  • ARK Genomic Revolution ETF
    4.73M3.42%
  • BIT Global Technology Leaders R-I
    1.59M1.15%